09:03 AM EDT, 10/24/2025 (MT Newswires) -- Kura Oncology ( KURA ) said Friday that it has received a $30 million milestone payment as part of its deal with Japanese pharmaceutical company Kyowa Kirin that was triggered by dosing the first patient in the KOMET-017 phase 3 studies of ziftomenib to treat myeloid leukemia.

The studies include two phase 3 trials to evaluate ziftomenib in combination with intensive and non-intensive chemotherapy in patients with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.

Shares of Kura Oncology ( KURA ) were up more than 5% in recent premarket activity Friday.

Price: 9.61, Change: +0.51, Percent Change: +5.60